The US Food and Drug Administration (FDA) is warning healthcare
professionals not to use intravenous versions of metronidazole,
ciprofloxacin, and ondansetron manufactured by Claris Lifesciences after
receiving reports of 2 contaminated intravenous bags.
The FDA stated that it received reports of floating white matter in 2
bags of Claris intravenous medications — 1 involving metronidazole, the
other ondansetron. Microbiological analysis identified the substance in
the metronidazole bag as a
Cladosporium mold, which can cause
infections in immunocompromised and other susceptible patients.
The metronidazole, ondansetron, and ciprofloxacin being recalled were
all produced on the same manufacturing line in the company's facilities
in Ahmedabad, India, where Claris is based. The company's Web site
states that Claris has 5 manufacturing facilities in Ahmedabad, some of
them approved by the FDA.
Sagent Pharmaceuticals, the distributor of metronidazole injection,
does not know of any adverse events caused by its product.
The lot numbers under recall are A090742, A090743, A090744, A090745,
A090746, A090769, A090770, A090771, A090772, A090773, A090774, A090775,
A090776, A090968, A091014, A000013, A000016, and A000019. Sagent
distributed these lots to hospitals, wholesalers, and distributors from
February through May 2010.
http://www.medscape.com/viewarticle/722743http://www.medscape.com/viewarticle/721982
Dr Vibhavari Naik, MD
Consultant Anesthesiologist,
Smile Train Project,
Nizams Institute of Medical Sciences,
Hyderabad, India.
E-mail:
vib...@yahoo.co.in Mobile:
+91 9959189958